Changes in Beneficial Ownership · 4
Century Therapeutics, Inc.
IPSCNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-08182026_080855.xml
Filing details
- Report period
- 2026-08-14
- Issuer
- Century Therapeutics, Inc.
- Issuer CIK
- 0001850119
- Trading symbol
- IPSC
Reporting owner 1
- Name
- Pfeiffenberger Brent
- Reporting owner CIK
- 0002001162
- Relationship
- Director · Officer
- Officer title
- President and CEO
- Address
- C/O CENTURY THERAPEUTICS, INC., 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA, 19104
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-14 | F · Form 4[F1] | 31,172 | D | 1.92 | 3,634,302 | D |
Table key
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.↩ 1
Signature 1
- Signed
- /s/ Douglas Carr, Attorney-in-Fact
- Date
- 2026-08-18
Company context
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of iPSC-derived cell therapies with the potential to meaningfully address autoimmune diseases, including T1D, and cancer. Century's therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.